Canadian DIN & Molecule SearchMolecules A–ZDrug ShortagesResourcesHealth Canada WeeklyRequest a Quote

RELEFACT TRH INJ 0.2MG/ML .2 MG — DIN 00376140

PROTIRELIN : .2 MG · HOECHST CANADA INC. · LIQUID · wholesale supply in Canada

Health Canada status: CANCELLED POST MARKET

What is RELEFACT TRH INJ 0.2MG/ML?

RELEFACT TRH INJ 0.2MG/ML .2 MG contains PROTIRELIN : .2 MG. It is listed in the Health Canada Drug Product Database under DIN 00376140, held by HOECHST CANADA INC., supplied as LIQUID for INTRAVENOUS administration. Health Canada currently lists it as cancelled post market, status dated 29-Aug-1996. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.

Is there a generic Protirelin in Canada, and who makes it?

Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.

3 holders have a Canadian DIN containing Protirelin, across 3 DINs, of which 0 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.

Market authorization holderDINsMarketedBrand namesPosition
HOECHST CANADA INC.10RELEFACT TRH INJ 0.2MG/MLNo marketed DIN
HOECHST ROUSSEL CANADA INC.10RELEFACT TRH INJECTION 200MCG/MLNo marketed DIN
ODAN LABORATORIES LTD10RELEFACT TRH INJECTION 200MCG/MLNo marketed DIN

Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.

How is it supplied and stored?

Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.

Strength on the label.2 MG
Dosage formLIQUID
RouteINTRAVENOUS

Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.

Substance and classification

Active substanceProtirelin
ATC codeV04CJ02
AHFS class36:60.00
Biosimilar biologicNo

Health Canada record and identifiers

The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.

DIN (8-digit, as used in ordering)00376140
DIN (unpadded, as printed on some documents)376140
Brand nameRELEFACT TRH INJ 0.2MG/ML
Generic / active ingredientPROTIRELIN : .2 MG
Market authorization holderHOECHST CANADA INC.
Health Canada schedulePrescription
ATC codeV04CJ02
ATC anatomical main groupV — Various
ATC therapeutic subgroupV04CJ
Current statusCANCELLED POST MARKET
Status date29-Aug-1996
Original market date1976-12-31 00:00:00
Status sourceLive Health Canada DPD sync

Verify on the primary sources

Health Canada DPD record

What can be used instead?

Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.

1 · Same molecule, other Canadian presentations

0 of 3 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.

ProductStrengthFormHolderHealth Canada statusDIN
RELEFACT TRH INJECTION 200MCG/ML200 MCGLIQUIDHOECHST ROUSSEL CANADA INC.CANCELLED POST MARKET01987763
RELEFACT TRH INJECTION 200MCG/ML200 MCGLIQUIDODAN LABORATORIES LTDCANCELLED POST MARKET02224615

2 · Same class — other molecules in ATC V04CJ

MoleculeCanadian brandsDINsMarketedSourceable
ProtirelinRELEFACT TRH INJ 0.2MG/ML · RELEFACT TRH INJECTION 200MCG/ML30Not in Canada

A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.

3 · Adjacent classes in ATC V04C

ATC subgroupMoleculesDINsMarketed
V04CXIndocyanine Green · Other Diagnostic Agents5916
V04CLTests For Allergic Diseases108
V04CCSincalide32
V04CGHistamine · Methylthionine · Pentagastrin51
V04CDTests For Pituitary Function11
V04CFTuberculin51
V04CHAminohippuric Acid · Indigo Carmine20
V04CKPancreozymin (Cholecystokinin) · Secretin20

Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.

Can this still be bought in Canada?

No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.

If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative

Ordering questions

Who can buy this from Nexara?

Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.

Is there a minimum order?

Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.

What is the lead time?

Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.

Why is there no price on this page?

Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.

Can Nexara supply this for a clinical trial?

Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.

Sources and disclaimer

Product data sourced from the Health Canada Drug Product Database. Health Canada status reconciled against the live DPD sync. Last reviewed 10 Sep 2026.

Nothing on this page is medical advice. Nexara Health is a licensed wholesale distributor and supplies licensed entities only; consumer orders are routed to a partner pharmacy. Alternatives tables describe supply, not clinical equivalence.

Health Canada Drug Product Database (DPD), DIN 00376140. Last reviewed 2026-09-10. Nexara Health is a licensed wholesaler and supplies licensed entities only; consumer orders are routed to a partner pharmacy.